Stephens Investment Management Group LLC lessened its holdings in PAREXEL International Corporation (NASDAQ:PRXL) by 48.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 253,494 shares of the medical research company’s stock after selling 242,858 shares during the period. Stephens Investment Management Group LLC owned about 0.50% of PAREXEL International Corporation worth $22,031,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in PRXL. BlackRock Inc. increased its stake in shares of PAREXEL International Corporation by 22,876.6% in the 1st quarter. BlackRock Inc. now owns 5,513,456 shares of the medical research company’s stock valued at $347,955,000 after purchasing an additional 5,489,460 shares in the last quarter. Credit Suisse AG increased its stake in shares of PAREXEL International Corporation by 1,897.2% in the 1st quarter. Credit Suisse AG now owns 2,093,297 shares of the medical research company’s stock valued at $132,108,000 after purchasing an additional 1,988,488 shares in the last quarter. Nomura Holdings Inc. increased its stake in shares of PAREXEL International Corporation by 189.6% in the 1st quarter. Nomura Holdings Inc. now owns 1,381,087 shares of the medical research company’s stock valued at $87,088,000 after purchasing an additional 904,236 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of PAREXEL International Corporation by 1,008.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 982,186 shares of the medical research company’s stock valued at $85,362,000 after purchasing an additional 893,551 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of PAREXEL International Corporation by 149.3% in the 1st quarter. Bank of America Corp DE now owns 630,020 shares of the medical research company’s stock valued at $39,760,000 after purchasing an additional 377,287 shares in the last quarter. Hedge funds and other institutional investors own 87.48% of the company’s stock.

Several brokerages recently weighed in on PRXL. Zacks Investment Research upgraded PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target for the company in a research note on Thursday, August 31st. BidaskClub lowered PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Jefferies Group LLC restated a “hold” rating and issued a $88.10 price target on shares of PAREXEL International Corporation in a research note on Wednesday, June 21st. Barclays PLC lowered PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target for the company. in a research note on Tuesday, June 20th. Finally, Raymond James Financial, Inc. upgraded PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research note on Tuesday, June 20th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $75.92.

COPYRIGHT VIOLATION WARNING: “PAREXEL International Corporation (PRXL) Position Decreased by Stephens Investment Management Group LLC” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/12/parexel-international-corporation-prxl-position-decreased-by-stephens-investment-management-group-llc.html.

PAREXEL International Corporation (NASDAQ:PRXL) traded up 0.05% during midday trading on Tuesday, reaching $87.89. The company’s stock had a trading volume of 246,443 shares. The firm has a market capitalization of $4.46 billion, a P/E ratio of 42.67 and a beta of 0.79. The company’s 50-day moving average is $87.65 and its 200 day moving average is $77.08. PAREXEL International Corporation has a 52 week low of $51.16 and a 52 week high of $87.95.

PAREXEL International Corporation (NASDAQ:PRXL) last issued its earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. The company had revenue of $557.20 million during the quarter, compared to analysts’ expectations of $537.59 million. During the same period last year, the company posted $0.94 earnings per share. Analysts expect that PAREXEL International Corporation will post $3.95 earnings per share for the current fiscal year.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.